Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249294 | 1.00 | PDGFRB (0.69) | PDGFRBKDRPARP1TGM2LRRK2 | |
| SCHEMBL14674887 | 0.91 | PDGFRB (0.77) | PDGFRBKDRPARP1TGM2MDM2 | |
| SCHEMBL14675150 | 0.91 | PDGFRB (0.77) | PDGFRBKDRPARP1TGM2MDM2 | |
| SCHEMBL14675079 | 0.90 | PDGFRB (0.64) | PDGFRBKDRPARP1TGM2MDM2 | |
| SCHEMBL14675080 | 0.90 | PDGFRB (0.64) | PDGFRBKDRPARP1TGM2MDM2 | |
| SCHEMBL13080901 | 0.88 | FLT3 (0.71) | PDGFRBKDRPARP1LRRK2FLT3 | |
| SCHEMBL3755030 | 0.88 | FLT3 (0.71) | PDGFRBKDRPARP1LRRK2FLT3 | |
| SCHEMBL3755027 | 0.88 | FLT3 (0.71) | PDGFRBKDRPARP1LRRK2FLT3 | |
| SCHEMBL13929117 | 0.86 | PDGFRB (0.60) | PDGFRBKDRTGM2LRRK2MDM2 | |
| SCHEMBL4723150 | 0.86 | PDGFRB (0.60) | PDGFRBKDRTGM2LRRK2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | claimed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | claimed |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-31 | — | — | US | claimed |
| EP-1856123-B1 | SMALL MOLECULE INHIBITORS OF MDM2 AND USES THEREOF | UNIV MICHIGAN (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8901117-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-12-02 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088931-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100273799-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-28 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-20060211757-A1 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | ERBB2, ABL1, IGF1R | PDGFRB 11/4885KDR 81/4885PARP1 636/4885 |
| US-20100273799-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | PDGFRB 3053/4885KDR 2853/4885PARP1 338/4885 |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | TP53, MDM2, CDKN1A | PDGFRB 2992/4885KDR 3007/4885PARP1 116/4885 |
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | PDGFRB 3053/4885KDR 2853/4885PARP1 338/4885 |
| US-20060211757-A1 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | SKP2, MDM2, CCAR2 | PDGFRB 1819/4885KDR 752/4885PARP1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.